Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders

Presentations Highlight New Data on Diagnostic Accuracy and Novel Biomarkers of Disease Severity in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that poster presentations from its bioMUSE natural history study of Multiple System Atrophy (MSA) will be delivered at the International Congress of Parkinson’s Disease and Movement Disorders taking place August 27 - 31, 2023 in Copenhagen, Denmark.

Title:	A multimodal approach for diagnosis of early Multiple System Atrophy
Presenter:	Daniel O. Claassen, M.D., M.S., Professor of Neurology, Vanderbilt University Medical Center
Abstract #:	162
Category:	Parkinsonism, Atypical: MSA
Date:	Monday, August 28, 2023
Time:	13:00 - 15:00 local time
Title:	Preliminary evidence for evolution of myoinositol and N-acetylaspartate as biomarkers of disease severity in early-stage Multiple System Atrophy
Presenter:	Paula Trujillo Diaz, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center
Abstract #:	181
Category:	Parkinsonism, Atypical: MSA
Date:	Monday, August 28, 2023
Time:	13:00 - 15:00 local time

About bioMUSE

Biomarkers of progression in Multiple System Atrophy (bioMUSE) is a natural history study that aims to track the progression of individuals with MSA, a parkinsonian disorder without approved therapy. The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under the direction of Daniel Claassen, M.D., M.S., Professor of Neurology and Principal Investigator. Natural history studies are important for characterizing disease progression in selected patient populations. The study has provided rich data for optimizing the design of Alterity’s randomized ATH434-201 Phase 2 clinical trial and enrolled approximately 20 individuals with clinically probable or clinically established MSA. BioMUSE continues to provide vital information on early stage MSA patients, informs the selection of biomarkers suitable to evaluate target engagement and preliminary efficacy, and delivers clinical data to characterize disease progression in a patient population that mirrors those currently enrolling in the Phase 2 clinical trial.